{"entity":{"id":"accession-therapeutics","kind":"company","name":"Accession Therapeutics","aka":[],"tldr":"Accession Therapeutics makes modified cold viruses that are designed to enter only cancer cells and deliver an immune-stimulating treatment inside the tumour. Its first product, ATTR-01, is in an early trial in solid tumours.","summary":"Accession Therapeutics Limited is an Oxford, UK, company led by chief executive Bent Jakobsen, who previously gave scientific direction to the T cell receptor companies Immunocore and Adaptimmune. Its TROCEPT platform engineers a 'stealth' virus with a viral point of entry intended to target cancer cells while bypassing healthy cells, and uses it to deliver immunotherapy payloads into tumours. The lead candidate TROCEPT-01 (ATTR-01) is given intravenously; TROCEPT-02 (ATTR-02) is the second programme. In December 2025 the company announced it had raised 30.5 million pounds (40 million US dollars) from existing investors to complete the phase 1 data for ATTR-01 and take ATTR-02 into the clinic. Its first registered cancer trial, the ATTEST master protocol NCT06977737, a phase 1/2 study of intravenous ATTR-01 in selected epithelial solid tumours at sites in Spain and the UK, was posted on ClinicalTrials.gov in May 2025.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.accessiontherapeutics.com/"},{"label":"Company news: 30.5 million pound financing, December 2025","url":"https://www.accessiontherapeutics.com/news-and-events"}],"tags":[],"related":[],"cancers":[],"sections":["immunotherapy"],"technologies":["oncolytic-virus"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06977737"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated on the company website.","The ATTR-01 payload is not named on the pages read; the registry record calls ATTR-01 a modified common cold virus that delivers an immune therapy drug into the cancer.","The funding round name and the identity of the existing investors were not stated on the page read.","Company website read on 29 October 2026."],"hq":"Oxford","country":"GB","companyType":"biotech","website":"https://www.accessiontherapeutics.com/","stage":"startup","investors":[],"funding":[{"round":"Financing","year":2025,"amountUsd":40000000,"source":"https://www.accessiontherapeutics.com/news-and-events","note":"Announced 4 December 2025 as 30.5 million pounds (40 million US dollars, as stated by the company) from existing investors."}]},"route":"/companies/accession-therapeutics/","neighbours":{"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"oncolytic-virus","kind":"technology","name":"Oncolytic viruses","route":"/technologies/oncolytic-virus/"}],"trial":[{"id":"nct06977737","kind":"trial","name":"A Study of ATTR-01 in Participants With Select Epithelial Solid Tumours","route":"/trials/nct06977737/"}]}}